Innate Pharma (IPHYF) Cash & Equivalents (2017 - 2025)

Innate Pharma's Cash & Equivalents history spans 9 years, with the latest figure at $32.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 53.91% year-over-year to $32.7 million; the TTM value through Dec 2025 reached $32.7 million, down 53.91%, while the annual FY2025 figure was $32.7 million, 54.5% down from the prior year.
  • Cash & Equivalents reached $32.7 million in Q4 2025 per IPHYF's latest filing, down from $71.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $118.7 million in Q4 2021 to a low of $32.7 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $76.8 million, with a median of $76.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: fell 6.6% in 2024, then crashed 53.91% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $118.7 million in 2021, then decreased by 27.6% to $85.9 million in 2022, then dropped by 11.59% to $76.0 million in 2023, then fell by 6.6% to $71.0 million in 2024, then plummeted by 53.91% to $32.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Cash & Equivalents are $32.7 million (Q4 2025), $71.0 million (Q4 2024), and $76.0 million (Q4 2023).